Gilead Sciences (NQ:GILD)

144.63 -0.11 (-0.08%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

78 79 Next >

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

April 09, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

Via Chartmill

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

2 Top Dividend Stocks That Could Set You Up for Life ↗

April 09, 2025

Via The Motley Fool

Topics Government Initial Public Offering Intellectual Property

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

Amazon, Alphabet, KLA And A Health Care Stock On CNBC's 'Final Trades' ↗

April 03, 2025

Via Benzinga

Intel's New CEO Outlines Recovery Strategy. Wall Street Remain Cautious. ↗

April 01, 2025

Intel's new CEO, Lip-Bu Tan, offered his strategy for turning around the troubled chipmaker in a speech late Monday. But Intel stock fell.

Via Investor's Business Daily

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

April 01, 2025

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

Via MarketBeat

1 Healthcare Stock to Target This Week and 2 to Turn Down

March 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗

March 27, 2025

Via Benzinga

What Analysts Are Saying About Gilead Sciences Stock ↗

March 27, 2025

Via Benzinga

A Closer Look at Gilead Sciences's Options Market Dynamics ↗

March 27, 2025

Via Benzinga

Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗

March 27, 2025

The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.

Via Investor's Business Daily

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

No Quick Fix For This Market ↗

March 23, 2025

Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis.

Via Talk Markets

Topics Stocks / Equities

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Which S&P500 stocks are gapping on Thursday? ↗

March 20, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed ↗

March 20, 2025

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Via Stocktwits

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

March 19, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

March 19, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Which S&P500 stocks are gapping on Wednesday? ↗

March 19, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding ↗

March 19, 2025

HIV prevention is a staple in Gilead Sciences' wheelhouse.

Via Investor's Business Daily

Wednesday's pre-market session: top gainers and losers in the S&P500 index ↗

March 19, 2025

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.

Via Chartmill

Crypto Mixed Post Trump-Putin Call; Trump Eyes HIV Program Cuts, Gilead Dips; Nvidia's AI Lead Secure Through 2028, Says JPMorgan – Top Headlines While The U.S. Slept ↗

March 19, 2025

Via Benzinga

Topics Artificial Intelligence Government

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides ↗

March 19, 2025

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the...

Via Benzinga

Topics Government

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

March 19, 2025

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Unpacking the Latest Options Trading Trends in Gilead Sciences ↗

March 18, 2025

Via Benzinga

Gilead Sciences - Leader In HIV Medicines ↗

March 14, 2025

The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline.

Via Talk Markets

Topics Stocks / Equities

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Is Gilead Sciences Gaining or Losing Market Support? ↗

March 13, 2025

Via Benzinga

GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why. ↗

March 13, 2025

A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors.

Via Chartmill

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.